Dyne Therapeutics, Inc. (DYN) Debt Components
- 2026-06-30: Long-term DebtUSD $199.33M; Long-Term Debt, Maturity, Year OneUSD $0.00; Long-Term Debt, Maturity, Year TwoUSD $0.00; Long-Term Debt, Maturity, Year ThreeUSD $0.00.
- 2026-03-31: Long-term DebtUSD $149.38M; Long-Term Debt, Maturity, Year OneUSD $0.00; Long-Term Debt, Maturity, Year TwoUSD $0.00; Long-Term Debt, Maturity, Year ThreeUSD $0.00.
- 2025-12-31: Long-term DebtUSD $148.92M; Long-Term Debt, Maturity, Year OneUSD (m); Long-Term Debt, Maturity, Year TwoUSD (m); Long-Term Debt, Maturity, Year ThreeUSD (m).
- 2025-12-31: Long-term DebtUSD (m); Long-Term Debt, Maturity, Year OneUSD $0.00; Long-Term Debt, Maturity, Year TwoUSD $0.00; Long-Term Debt, Maturity, Year ThreeUSD $0.00.
Dyne Therapeutics, Inc. Debt Components
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Long-term Debt USD | Long-Term Debt, Maturity, Year One USD | Long-Term Debt, Maturity, Year Two USD | Long-Term Debt, Maturity, Year Three USD | Long-Term Debt, Maturity, Year Four USD | Long-Term Debt, Maturity, Year Five USD | Long-Term Debt, Maturity, after Year Five USD | Long-term Debt, Gross USD | Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net USD | Long-term Debt, Excluding Current Maturities USD |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $199.33M | $0.00 | $0.00 | $0.00 | $89.50M | $110.50M | (m) | $200.00M | $2.01M | (m) |
| 2026-03-31 | $149.38M | $0.00 | $0.00 | $0.00 | $67.13M | $82.87M | (m) | $150.00M | $1.55M | (m) |
| 2025-12-31 | $148.92M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-12-31 | (m) | $0.00 | $0.00 | $0.00 | $0.00 | $67.13M | $82.87M | $150.00M | $1.62M | (m) |
| 2025-09-30 | $99.15M | $0.00 | $0.00 | $0.00 | $22.07M | $47.65M | $30.27M | $100.00M | $1.14M | (m) |
| 2025-06-30 | $98.81M | $0.00 | $0.00 | $0.00 | $22.23M | $47.86M | $29.91M | $100.00M | $1.20M | (m) |
| 2024-12-31 | $0.00 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $9.94M |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |